查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1386507

病毒载体製造市场报告：2030 年趋势、预测与竞争分析

Viral Vector Manufacturing Market Report: Trends, Forecast and Competitive Analysis to 2030
出版日期: | 出版商: Lucintel | 英文 150 Pages | 商品交期: 3个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

病毒载体製造趋势与预测

预计到 2030 年，全球病毒载体製造市场将达到 30 亿美元，2024 年至 2030 年年复合成长率为 18.7%。该市场的主要驱动因素是对基于病毒载体的治疗的需求不断增加、对病毒载体製造的投资增加以及病毒载体製造的技术进步。全球病毒载体製造市场的未来前景广阔，製药、生物製药和研究机构市场充满机会。

病毒载体製造市场洞察

Lucintel 预测，由于对治疗癌症、罕见疾病和遗传性疾病等多种疾病的细胞和基因疗法的需求不断增加，细胞和基因疗法将在预测期内实现最高增长。

在这个市场中，製药和生物製药公司是最大的细分市场，因为它们开发和商业化基于病毒载体的治疗方法，治疗多种疾病，包括癌症、罕见疾病和感染疾病。这似乎将继续成为市场的焦点。案件。

由于该地区製药和生物技术行业对基于病毒载体的疗法的需求不断增加，预计北美在预测期内将出现最高增长。

本报告回答了 11 个关键问题：

  • Q.1. 细分市场中最有前途和高成长的机会是什么？
  • Q.2.哪个细分市场将以更快的速度成长？为什么？
  • Q.3.您认为哪些地区未来会出现更快的成长？为什么？
  • Q.4. 影响市场动态的主要因素有哪些？市场的主要挑战和商业风险是什么？
  • Q.5. 这个市场的商业风险和竞争威胁是什么？
  • Q.6.这个市场有哪些新趋势？为什么？
  • Q.7.市场客户需求有何改变？
  • Q.8. 该市场有哪些新发展以及哪些公司处于领先地位？
  • Q.9.这个市场的主要企业有哪些？主要企业采取哪些策略配合措施来发展业务？
  • Q.10. 该市场上的竞争产品有哪些？由于材料或产品替代而导致市场占有率下降的威胁有多大？
  • Q.11.过去年度发生了哪些併购事件，对产业产生了哪些影响？

目录

第1章执行摘要

第2章全球病毒载体製造市场：市场动态

  • 简介、背景、分类
  • 供应链
  • 产业驱动因素与挑战

第3章2018-2030年市场趋势及预测分析

  • 宏观经济趋势（2018-2023）与预测（2024-2030）
  • 全球病毒载体製造市场趋势（2018-2023）与预测（2024-2030）
  • 按类型分類的全球病毒载体製造市场
    • 腺病毒
    • 逆转录病毒
    • 腺结合病毒
    • 慢病毒
    • 质粒DNA
    • 其他的
  • 按工作流程分類的全球病毒载体製造市场
    • 上游製造
    • 下游製造
  • 全球病毒载体製造市场（按应用）
    • 细胞和基因治疗
    • 疫苗学
    • 研究及其他
  • 按最终用途分類的全球病毒载体製造市场
    • 药品和生物製药
    • 研究机构
    • 其他的

第4章2018-2030年分地区市场趋势及预测分析

  • 全球病毒载体製造市场（按地区）
  • 北美洲病毒载体製造市场
  • 欧洲病毒载体製造市场
  • 亚太病毒载体製造市场
  • 其他区域病毒载体製造市场

第5章竞争分析

  • 产品系列分析
  • 营运整合
  • 波特五力分析

第6章成长机会与策略分析

  • 成长机会分析
    • 按类型分類的全球病毒载体製造市场成长机会
    • 按工作流程分類的全球病毒载体製造市场成长机会
    • 全球病毒载体製造市场成长机会（按应用）
    • 全球病毒载体製造市场成长机会（依最终用途）
    • 按地区分類的全球病毒载体製造市场成长机会
  • 全球病毒载体製造市场的新兴趋势
  • 战略分析
    • 新产品开发
    • 扩大全球病毒载体製造市场的产能
    • 全球病毒载体製造市场的合併、收购和合资企业
    • 认证和许可

第7章主要企业概况

  • Merck
  • Lonza
  • FUJIFILM Diosynth Biotechnologies
  • Thermo Fisher Scientific
  • Cobra Biologics
  • Catalent
  • Wuxi Biologics
  • Takara Bio
  • Waisman Biomanufacturing
  • Genezen laboratories
简介目录

Viral Vector Manufacturing Trends and Forecast

The future of the global viral vector manufacturing market looks promising with opportunities in the pharmaceutical & biopharmaceutical and research institutes markets. The global viral vector manufacturing market is expected to reach an estimated $3.0 billion by 2030 with a CAGR of 18.7% from 2024 to 2030. The major drivers for this market are increasing demand for viral vector-based therapies, growing investment in viral vector manufacturing, and technological advancements in viral vector manufacturing.

A more than 150-page report is developed to help in your business decisions.

Viral Vector Manufacturing by Segment

The study includes a forecast for the global viral vector manufacturing by type, workflow, application, end use, and region.

Viral Vector Manufacturing Market by Type [Shipment Analysis by Value from 2018 to 2030]:

  • Adenovirus
  • Retrovirus
  • Adeno-Associated Virus
  • Lentivirus
  • Plasmid DNA
  • Others

Viral Vector Manufacturing Market by Workflow [Shipment Analysis by Value from 2018 to 2030]:

  • Upstream Manufacturing
  • Downstream Manufacturing

Viral Vector Manufacturing Market by Application [Shipment Analysis by Value from 2018 to 2030]:

  • Cell & Gene Therapy
  • Vaccinology
  • Research & Other Applications

Viral Vector Manufacturing Market by End Use [Shipment Analysis by Value from 2018 to 2030]:

  • Pharmaceutical & Biopharmaceutical
  • Research Institutes
  • Others

Viral Vector Manufacturing Market by Region [Shipment Analysis by Value from 2018 to 2030]:

  • North America
  • Europe
  • Asia Pacific
  • The Rest of the World

List of Viral Vector Manufacturing Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies viral vector manufacturing companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the viral vector manufacturing companies profiled in this report include-

  • Merck
  • Lonza
  • Fujifilm Diosynth Biotechnologies
  • Thermo Fisher Scientific
  • Cobra Biologics
  • Catalent
  • Wuxi Biologics
  • Takara Bio
  • Waisman Biomanufacturing
  • Genezen Laboratories

Viral Vector Manufacturing Market Insights

Lucintel forecasts that cell and gene therapy is expected to witness highest growth over the forecast period due to growing demand for cell and gene therapies for the treatment of a wide range of diseases, including cancer, rare diseases, and genetic disorders.

Within this market, pharmaceutical and biopharmaceutical will remain the largest segment due to the fact that these pharmaceutical and biopharmaceutical companies companies are developing and commercializing viral vector-based therapies for a wide range of diseases, including cancer, rare diseases, and infectious diseases.

North America is expected to witness highest growth over the forecast period due to increasing demand for viral vector-based therapies from the pharmaceutical and biotechnology industries in the region.

Features of the Global Viral Vector Manufacturing Market

Market Size Estimates: Viral vector manufacturing market size estimation in terms of value ($B).

Trend and Forecast Analysis: Market trends (2018 to 2023) and forecast (2024 to 2030) by various segments and regions.

Segmentation Analysis: Viral vector manufacturing market size by various segments, such as by type, workflow, application, end use, and region in terms of value ($B).

Regional Analysis: Viral vector manufacturing market breakdown by North America, Europe, Asia Pacific, and Rest of the World.

Growth Opportunities: Analysis of growth opportunities in different types, workflows, applications, end uses, and regions for the viral vector manufacturing market.

Strategic Analysis: This includes M&A, new product development, and competitive landscape of the viral vector manufacturing market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

FAQ

Q.1 What is the viral vector manufacturing market size?

Answer: The global viral vector manufacturing market is expected to reach an estimated $3.0 billion by 2030.

Q.2 What is the growth forecast for viral vector manufacturing market?

Answer: The global viral vector manufacturing market is expected to grow with a CAGR of 18.7% from 2024 to 2030.

Q.3 What are the major drivers influencing the growth of the viral vector manufacturing market?

Answer: The major drivers for this market are increasing demand for viral vector-based therapies, growing investment in viral vector manufacturing and technological advancements in viral vector manufacturing.

Q4. What are the major segments for viral vector manufacturing market?

Answer: The future of the viral vector manufacturing market looks promising with opportunities in the pharmaceutical & biopharmaceutical and research institutes markets.

Q5. Who are the key viral vector manufacturing market companies?

Answer: Some of the key viral vector manufacturing companies are as follows:

  • Merck
  • Lonza
  • Fujifilm Diosynth Biotechnologies
  • Thermo Fisher Scientific
  • Cobra Biologics
  • Catalent
  • Wuxi Biologics
  • Takara Bio
  • Waisman Biomanufacturing
  • Genezen Laboratories

Q6. Which viral vector manufacturing market segment will be the largest in future?

Answer: Lucintel forecasts that cell and gene therapy is expected to witness highest growth over the forecast period due to growing demand for cell and gene therapies for the treatment of a wide range of diseases, including cancer, rare diseases, and genetic disorders.

Q7. In viral vector manufacturing market, which region is expected to be the largest in next 5 years?

Answer: North America is expected to witness highest growth over the forecast period due to increasing demand for viral vector-based therapies from the pharmaceutical and biotechnology industries in the region.

Q.8 Do we receive customization in this report?

Answer: Yes, Lucintel provides 10% customization without any additional cost.

This report answers following 11 key questions:

  • Q.1. What are some of the most promising, high-growth opportunities for the viral vector manufacturing market by type (adenovirus, retrovirus, adeno-associated virus, lentivirus, plasmid DNA, and others), workflow (upstream manufacturing and downstream manufacturing), application (cell & gene therapy, vaccinology, and research & other applications), end use (pharmaceutical & biopharmaceutical, research institutes, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
  • Q.2. Which segments will grow at a faster pace and why?
  • Q.3. Which region will grow at a faster pace and why?
  • Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
  • Q.5. What are the business risks and competitive threats in this market?
  • Q.6. What are the emerging trends in this market and the reasons behind them?
  • Q.7. What are some of the changing demands of customers in the market?
  • Q.8. What are the new developments in the market? Which companies are leading these developments?
  • Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
  • Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
  • Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?

Table of Contents

1. Executive Summary

2. Global Viral Vector Manufacturing Market : Market Dynamics

  • 2.1: Introduction, Background, and Classifications
  • 2.2: Supply Chain
  • 2.3: Industry Drivers and Challenges

3. Market Trends and Forecast Analysis from 2018 to 2030

  • 3.1. Macroeconomic Trends (2018-2023) and Forecast (2024-2030)
  • 3.2. Global Viral Vector Manufacturing Market Trends (2018-2023) and Forecast (2024-2030)
  • 3.3: Global Viral Vector Manufacturing Market by Type
    • 3.3.1: Adenovirus
    • 3.3.2: Retrovirus
    • 3.3.3: Adeno-Associated Virus
    • 3.3.4: Lentivirus
    • 3.3.5: Plasmid DNA
    • 3.3.6: Others
  • 3.4: Global Viral Vector Manufacturing Market by Workflow
    • 3.4.1: Upstream Manufacturing
    • 3.4.2: Downstream Manufacturing
  • 3.5: Global Viral Vector Manufacturing Market by Application
    • 3.5.1: Cell & Gene Therapy
    • 3.5.2: Vaccinology
    • 3.5.3: Research & Other Applications
  • 3.6: Global Viral Vector Manufacturing Market by End Use
    • 3.6.1: Pharmaceutical & Biopharmaceutical
    • 3.6.2: Research Institutes
    • 3.6.3: Others

4. Market Trends and Forecast Analysis by Region from 2018 to 2030

  • 4.1: Global Viral Vector Manufacturing Market by Region
  • 4.2: North American Viral Vector Manufacturing Market
    • 4.2.2: North American Viral Vector Manufacturing Market by End Use: Pharmaceutical & Biopharmaceutical, Research Institutes, and Others
  • 4.3: European Viral Vector Manufacturing Market
    • 4.3.1: European Viral Vector Manufacturing Market by Application: Cell & Gene Therapy, Vaccinology, and Research & Other Applications
    • 4.3.2: European Viral Vector Manufacturing Market by End Use: Pharmaceutical & Biopharmaceutical, Research Institutes, and Others
  • 4.4: APAC Viral Vector Manufacturing Market
    • 4.4.1: APAC Viral Vector Manufacturing Market by Application: Cell & Gene Therapy, Vaccinology, and Research & Other Applications
    • 4.4.2: APAC Viral Vector Manufacturing Market by End Use: Pharmaceutical & Biopharmaceutical, Research Institutes, and Others
  • 4.5: ROW Viral Vector Manufacturing Market
    • 4.5.1: ROW Viral Vector Manufacturing Market by Application: Cell & Gene Therapy, Vaccinology, and Research & Other Applications
    • 4.5.2: ROW Viral Vector Manufacturing Market by End Use: Pharmaceutical & Biopharmaceutical, Research Institutes, and Others

5. Competitor Analysis

  • 5.1: Product Portfolio Analysis
  • 5.2: Operational Integration
  • 5.3: Porter's Five Forces Analysis

6. Growth Opportunities and Strategic Analysis

  • 6.1: Growth Opportunity Analysis
    • 6.1.1: Growth Opportunities for the Global Viral Vector Manufacturing Market by Type
    • 6.1.2: Growth Opportunities for the Global Viral Vector Manufacturing Market by Workflow
    • 6.1.3: Growth Opportunities for the Global Viral Vector Manufacturing Market by Application
    • 6.1.4: Growth Opportunities for the Global Viral Vector Manufacturing Market by End Use
    • 6.1.5: Growth Opportunities for the Global Viral Vector Manufacturing Market by Region
  • 6.2: Emerging Trends in the Global Viral Vector Manufacturing Market
  • 6.3: Strategic Analysis
    • 6.3.1: New Product Development
    • 6.3.2: Capacity Expansion of the Global Viral Vector Manufacturing Market
    • 6.3.3: Mergers, Acquisitions, and Joint Ventures in the Global Viral Vector Manufacturing Market
    • 6.3.4: Certification and Licensing

7. Company Profiles of Leading Players

  • 7.1: Merck
  • 7.2: Lonza
  • 7.3: FUJIFILM Diosynth Biotechnologies
  • 7.4: Thermo Fisher Scientific
  • 7.5: Cobra Biologics
  • 7.6: Catalent
  • 7.7: Wuxi Biologics
  • 7.8: Takara Bio
  • 7.9: Waisman Biomanufacturing
  • 7.10: Genezen laboratories